Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus

Title: Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus
Authors: Atzeni F.; Gozza F.; Riva A.; Alciati A.; Galloway J.
Contributors: Atzeni, F.; Gozza, F.; Riva, A.; Alciati, A.; Galloway, J.
Publisher Information: Taylor and Francis Ltd.
Publication Year: 2023
Collection: Università degli Studi di Messina: IRIS
Subject Terms: bDMARD; cDMARD; Herpes zoster; HZ; JAK inhibitor; rheumatoid arthriti; spondyloarthritis
Description: Introduction: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs), and more recently of Janus kinase inhibitors (JAKi), has had a major impact on the herpes zoster (HZ) reactivation, which represents an important clinical challenge in the treatment of inflammatory arthritis (IA) in patients with a complete pharmacological control of peripheral inflammation. Areas covered: In this review, we provide an overview on the effects of conventional DMARDs/ bDMARDs and JAKi on HZ reactivation. Furthermore, we underline the controversial findings and the potential management strategies. We searched PubMed, Medline, and the Cochrane Library for papers published between 1995 and November 2022. Expert opinion: The overall data showed a slightly higher risk of HZ in patients treated with bDMARDs, and more pronounced for those treated with JAKi. As management strategies, we suggest an effective vaccination campaign and a focus on early diagnosis.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/36946287; info:eu-repo/semantics/altIdentifier/wos/WOS:000956671400001; volume:24; issue:6; firstpage:679; lastpage:689; numberofpages:11; journal:EXPERT OPINION ON PHARMACOTHERAPY; https://hdl.handle.net/11570/3272448
DOI: 10.1080/14656566.2023.2195050
Availability: https://hdl.handle.net/11570/3272448; https://doi.org/10.1080/14656566.2023.2195050
Accession Number: edsbas.A5C764E1
Database: BASE